Drug Profile
Influenza A virus vaccine H5N1 - GC Biopharma/Mogam Biotechnology Research Institute
Alternative Names: MG 1109Latest Information Update: 01 Apr 2022
Price :
$50
*
At a glance
- Originator Green Cross
- Developer GC Biopharma
- Class Influenza A virus H5N1 vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Influenza A virus H5N1 subtype
Most Recent Events
- 29 Mar 2022 GC Pharma is now called GC Biopharma
- 15 Feb 2016 MG 1109 is still in development for Influenza-A virus H5N1 subtype (prevention) in South Korea
- 01 Mar 2014 Green Cross Corporation completes a phase III trial in Influenza-A virus H5N1 subtype (prevention) in South Korea (NCT01987011)